Inclusion of an extended treatment with recovery improves the results for the human peripheral blood lymphocyte micronucleus assay.


Journal

Mutagenesis
ISSN: 1464-3804
Titre abrégé: Mutagenesis
Pays: England
ID NLM: 8707812

Informations de publication

Date de publication:
20 09 2019
Historique:
received: 08 11 2018
revised: 22 03 2019
accepted: 03 05 2019
pubmed: 19 6 2019
medline: 1 5 2020
entrez: 19 6 2019
Statut: ppublish

Résumé

The in vitro micronucleus (IVMN) test was endorsed for regulatory genotoxicity testing with adoption of the Organisation for Economic Co-operation and Development (OECD) test guideline (TG) 487 in 2010. This included two equally acceptable options for extended treatment in the absence of metabolic activation: a treatment for 1.5-2.0 cell cycles with harvest at the end of treatment (Option A) or treatment for 1.5-2.0 cell cycles followed by recovery for 1.5-2.0 cell cycles prior to harvest (Option B). Although no preferences were discussed, TG 487 cautions that Option B may not be appropriate for stimulated lymphocytes where exponential growth may be declining at 96 h after phytohaemagglutinin (PHA) stimulation. Following revision of TG 487 in 2014 and 2016, emphasis has been placed on using Option A. Given the purpose of the IVMN assay is to determine both clastogenic and aneugenic potential, the authors believe the assay is compromised if an extended treatment with recovery is not included for sensitive detection of certain classes of chemical. In this study, average generation time (via bromodeoxyuridine incorporation) of human peripheral blood lymphocytes (HPBL) was measured up to 144 h after PHA stimulation. In addition, the HPBL micronucleus (MN) assay was performed using Option A and B treatment schedules. Cytotoxicity (replication index) and MN induction were determined following treatment with 14 chemicals. The data demonstrate that lymphocytes actively divide beyond 96 h after PHA stimulation. Furthermore, MN induction was only observed with some aneugenic chemicals and nucleoside analogues in HPBLs following extended treatment with a recovery period. For the majority of chemicals tested the magnitude of MN induction was generally greater and MN induction was observed across a wider concentration range following the Option B treatment schedule. In addition, steep concentration-related toxicity following treatment without recovery is more common, making selection of suitable concentrations (within regulatory toxicity limits) for MN analysis challenging.

Identifiants

pubmed: 31209484
pii: 5519752
doi: 10.1093/mutage/gez011
doi:

Substances chimiques

Anti-HIV Agents 0
Antineoplastic Agents 0
Mutagens 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

217-237

Informations de copyright

© The Author(s) 2019. Published by Oxford University Press on behalf of the UK Environmental Mutagen Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

James Whitwell (J)

Covance Laboratories Ltd, Genetic Toxicology, Harrogate, North Yorkshire, UK.

Robert Smith (R)

Covance Laboratories Ltd, Genetic Toxicology, Harrogate, North Yorkshire, UK.

Teresa Chirom (T)

Covance Laboratories Ltd, Genetic Toxicology, Harrogate, North Yorkshire, UK.

Gary Watters (G)

Covance Laboratories Ltd, Genetic Toxicology, Harrogate, North Yorkshire, UK.

Victoria Hargreaves (V)

Covance Laboratories Ltd, Genetic Toxicology, Harrogate, North Yorkshire, UK.

Mel Lloyd (M)

Covance Laboratories Ltd, Genetic Toxicology, Harrogate, North Yorkshire, UK.

Sarah Phillips (S)

Covance Laboratories Ltd, Genetic Toxicology, Harrogate, North Yorkshire, UK.

Julie Clements (J)

Covance Laboratories Ltd, Genetic Toxicology, Harrogate, North Yorkshire, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH